Sort
30,917 grants matching “tumor microenvironment”
PROTAC Targeting of Tip60 in Syngeneic Cancer Models Using Cereblon Knock-in Mice
$388,077Wayne William Hancock · Children'S Hosp Of Philadelphia · R01 · FY2022 · CA
PROTAC Targeting of Tip60 in Syngeneic Cancer Models Using Cereblon Knock-in Mice
$388,077Wayne William Hancock · Children'S Hosp Of Philadelphia · R01 · FY2023 · CA
Project 3: Modulation of the head and neck tumor immune microenvironment by targeting the TAM family of receptors
$388,023Deric L Wheeler · University Of Wisconsin-Madison · P50 · FY2025 · CA
Targeting DNA repair to eradicate TKi-refractory/resistant CML and Ph+ALL
$388,003Tomasz Skorski · Temple Univ Of The Commonwealth · R01 · FY2022 · CA
New Multi-Drug Resistance Mechanism in Multiple Myeloma
$388,003Shigeki Miyamoto · University Of Wisconsin-Madison · R01 · FY2021 · CA
Targeting DNA repair to eradicate TKi-refractory/resistant CML and Ph+ALL
$387,997Tomasz Skorski · Temple Univ Of The Commonwealth · R01 · FY2021 · CA
Explore the therapeutic potential of small-molecule immune modulators
$387,977Chuo Chen · Ut Southwestern Medical Center · R01 · FY2019 · CA
Explore the therapeutic potential of small-molecule immune modulators
$387,977Chuo Chen · Ut Southwestern Medical Center · R01 · FY2021 · CA
Explore the therapeutic potential of small-molecule immune modulators
$387,977Chuo Chen · Ut Southwestern Medical Center · R01 · FY2020 · CA
Targeting tumorigenic pathways in glioblastoma with oncolytic HSV
$387,855Samuel D Rabkin · Massachusetts General Hospital · R01 · FY2022 · CA
Targeting tumorigenic pathways in glioblastoma with oncolytic HSV
$387,855Samuel D Rabkin · Massachusetts General Hospital · R01 · FY2023 · CA
Tumor Immunology & Host Response
$387,787Max S. Wicha · University Of Michigan At Ann Arbor · P30 · FY2016 · CA
Coordinating tumor differentiation and immune suppression with the metabolic state and treatment outcome
$387,785Hans Ragnar Widlund · Brigham And Women'S Hospital · R01 · FY2019 · CA
Project 1: Targeting the PD-1 pathway in HCC
$387,766Ahmed Kaseb · University Of Tx Md Anderson Can Ctr · P50 · FY2020 · CA
Biomarker Developmental Laboratory (BDL)
$387,766Steven J Skates · Massachusetts General Hospital · U2C · FY2025 · CA
Role of Tumor Stem Cells Recurrent Prostate Cancer
$387,762Gary Smith · Univ Of North Carolina Chapel Hill · P01 · FY2014 · CA
Cancer Cell Intrinsic Interferon-I pathway Activation by Fractionated Radiation
$387,731Sandra Demaria · Weill Medical Coll Of Cornell Univ · R01 · FY2017 · CA
NK cell exhaustion in metastatic melanoma
$387,731Nina Bhardwaj · Icahn School Of Medicine At Mount Sinai · R01 · FY2018 · CA
Harnessing Csf-2 compartmentalized role on tissue resident phagocytes to uncouple anti-tumoral from pathological immunity induced by checkpoint inhibitors
$387,731Miriam Merad · Icahn School Of Medicine At Mount Sinai · R01 · FY2015 · CA
Dectin-1 signaling drives pancreatic oncogenesis by inducing macrophage-mediated adaptive immune suppression
$387,731George Miller · New York University School Of Medicine · R01 · FY2018 · CA
Investigating T Cell Egress via Lymphatic Vessels in Melanoma
$387,731Amanda W. Lund · New York University School Of Medicine · R01 · FY2020 · CA
Cellular and molecular mechanism of Hippo signaling in suppressing liver tumor formation
$387,731Yingzi Yang · Harvard Medical School · R01 · FY2021 · CA
Cellular and molecular mechanism of Hippo signaling in suppressing liver tumor formation
$387,731Yingzi Yang · Harvard Medical School · R01 · FY2020 · CA
Harnessing Csf-2 compartmentalized role on tissue resident phagocytes to uncouple anti-tumoral from pathological immunity induced by checkpoint inhibitors
$387,731Miriam Merad · Icahn School Of Medicine At Mount Sinai · R01 · FY2018 · CA
Potentiating Checkpoint Blockade by Cross-Priming Tumor-Reactive T cells with In Situ Vaccination
$387,731Joshua D Brody · Icahn School Of Medicine At Mount Sinai · R37 · FY2021 · CA